Biophage Pharma prepares to meet increased demand for Beryllium and MELISA(R) testing - Dr. Michel Heyne will become director of the Beryllium Reference Lab to help expedite its INSPQ accreditation
Tuesday January 30, 9:00 am ET
MONTREAL, Jan. 30 /CNW Telbec/ - (TSX.V: BUG) - Biophage Pharma Inc. (Biophage) today announced the hiring of Dr. Michel Heyne as director of its Beryllium Reference Lab to meet the increasing demand for Beryllium and MELISA(R) testing. With his vast experience in laboratory testing this eminent haematologist will help expedite the accreditation process of Biophage's Beryllium laboratory by the Quebec National Institute of Public Health (INSPQ).
Dr. Heyne brings more than 38 years experience in the hematology field to Biophage. He was an active member of the medical team at Hôpital Hotel-Dieu in St-Jerome for more than 35 years where he acted as director of the Department of Internal Medicine, head of Hemato-oncology services, and head of the Laboratories Department. He was also the founder of the Hematology and Hemato-oncology laboratories at Hotel-Dieu. For more than 26 years, Dr Heyne was also a consultant in Hemato-oncology for the Hospital Centers of Argenteuil and Laurentien.
Dr. Mandeville, President and CEO of Biophage commented, "We are extremely pleased to welcome Dr. Heyne to our Immunotox Labs team. Dr. Heyne brings to Biophage a wealth of experience and expertise in the field of hematology and laboratory testing as well as an in-depth knowledge of the field and its basic unmet needs. His extensive network of contacts in North America and Europe will help our team identify new markets for Beryllium and MELISA(R) testing."
About Biophage Pharma Inc.
Biophage Pharma is a high potential, revenue-driven Canadian biotechnology company focused on the development of innovative phage-based products and technologies for the detection and management of bacterial contaminations. Founded in 1995, Biophage operates three divisions: (1) The phage therapy division for the management of bacterial contaminations in the medical, veterinary and environment fields; (2) The Biosensors division for the development and commercialization of Biosensors, more particularly a portable PDS(R) Biosensor which is entering in the pre-commercialization stage; (3) The Immunotox Labs division, which provides services in Immunogenicity and Immunotoxicity, Nanotoxicity and Ecotoxicology, Beryllium sensitivity testing and MELISA(R) testing for the detection of sensitization to more than 200 different allergens including metals, penicillin, gluten and pollens. (www.biophagepharma.net ; www.immunotoxlabs.net).
The TSX Venture Exchange does not accept responsibility for the adequacy
or accuracy of this release.
